11:56 ET - Doximity's underperformance in stock price since October is a sign of substantial upside potential, Morgan Stanley analysts write in a note. "We view DOCS as a coiled spring for a material move higher on any positive developments," they write, naming the health technology firm as a top battleground stock for 2026. There's been negative sentiment from investors around an apparent deceleration in growth in the fiscal third quarter and the threat of losing market share to OpenEvidence. But the analysts see space for both companies to succeed, and advise against overlooking solid growth on a full-year basis, suggesting strong business fundamentals. "This is the best setup we've seen on the long side in a couple of years," they write. Shares are up 3.2% to $44.68.(elias.schisgall@wsj.com)

(END) Dow Jones Newswires

January 05, 2026 11:56 ET (16:56 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.